Prothrombotic mechanisms and anticoagulant therapy in dogs with immune-mediated hemolytic anemia

Journal of Veterinary Emergency and Critical Care

Volumn 23, Issue 1, 2013, Pages 3-13

  Kidd, Linda ^a   Mackman, Nigel ^b  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Aspirin; Clopidogrel; Hemostasis; Heparin; Microparticle; Tissue factor

Indexed keywords

ANTICOAGULANT AGENT;

ANIMAL; ANIMAL DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; DOG; DOG DISEASE; REVIEW; THROMBOSIS;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; ANTICOAGULANTS; DOG DISEASES; DOGS; THROMBOSIS;

EID: 84873166951     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2012.00824.x     Document Type: Review

References (114)

1. Carr AP, Panciera DL, Kidd L. Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: a retrospective study of 72 dogs. J Vet Intern Med 2002; 16(5):504-509.
2. Klag AR, Giger U, Shofer FS. Idiopathic immune-mediated hemolytic anemia in dogs: 42 cases (1986-1990). J Am Vet Med Assoc 1993; 202(5):783-788.
3. McAlees TJ. Immune-mediated haemolytic anaemia in 110 dogs in Victoria, Australia. Aust Vet J 2010; 88(1-2):25-28.
4. Piek CJ, Junius G, Dekker A, et al. Idiopathic immune-mediated hemolytic anemia: treatment outcome and prognostic factors in 149 dogs. J Vet Intern Med 2008; 22(2):366-373.
5. Weinkle TK, Center SA, Randolph JF, et al. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). J Am Vet Med Assoc 2005; 226(11):1869-1880.
6. Adachi K, Yoshimoto A, Hasegawa T, et al. Anti-erythrocyte membrane antibodies detected in sera of dogs naturally infected with Babesia gibsoni. J Vet Med Sci 1992; 54(6):1081-1084.
7. Breitschwerdt EB, Maggi RG, Chomel BB, et al. Bartonellosis: an emerging infectious disease of zoonotic importance to animals and human beings. J Vet Emerg Crit Care 2010; 20(1):8-30.
8. Carli E, Tasca S, Trotta M, et al. Detection of erythrocyte binding IgM and IgG by flow cytometry in sick dogs with Babesia canis canis or Babesia canis vogeli infection. Vet Parasitol 2009; 162(1-2):51-57.
9. Conrad P, Thomford J, Yamane I, et al. Hemolytic anemia caused by Babesia gibsoni infection in dogs. J Am Vet Med Assoc 1991; 199(5):601-605.
10. Duval D, Giger U. Vaccine-associated immune-mediated hemolytic anemia in the dog. J Vet Intern Med 1996; 10(5):290-295.
11. Frank JR, Breitschwerdt EB. A retrospective study of ehrlichiosis in 62 dogs from North Carolina and Virginia. J Vet Intern Med 1999; 13(3):194-201.
12. Mazepa AW, Kidd LB, Young KM, et al. Clinical presentation of 26 anaplasma phagocytophilum-seropositive dogs residing in an endemic area. J Am Anim Hosp Assoc 2010; 46(6):405-412.
13. Mellanby RJ, Holloway A, Chantrey J, et al. Immune-mediated haemolytic anaemia associated with a sarcoma in a flat-coated retriever. J Small Anim Pract 2004; 45(1):21-24.
14. Messick JB. New perspectives about hemotrophic mycoplasma (formerly, Haemobartonella and Eperythrozoon species) infections in dogs and cats. Vet Clin North Am Small Anim Pract 2003; 33(6):1453-1465.
15. Smee NM, Harkin KR, Wilkerson MJ. Measurement of serum antinuclear antibody titer in dogs with and without systemic lupus erythematosus: 120 cases (1997-2005). J Am Vet Med Assoc 2007; 230(8):1180-1183.
16. Burgess K, Moore A, Rand W, et al. Treatment of immune-mediated hemolytic anemia in dogs with cyclophosphamide. J Vet Intern Med 2000; 14(4):456-462.
17. Goggs R, Wiinberg B, Kjelgaard-Hansen M, et al. Serial assessment of the coagulation status of dogs with immune-mediated haemolytic anaemia using thromboelastography. Vet J 2011; 191(3):347-353.
18. Mellett AM, Nakamura RK, Bianco D. A prospective study of clopidogrel therapy in dogs with primary immune-mediated hemolytic anemia. J Vet Intern Med 2011; 25(1):71-75.
19. Reimer ME, Troy GC, Warnick LD. Immune-mediated hemolytic anemia: 70 cases (1988-1996). J Am Anim Hosp Assoc 1999; 35(5):384-391.
20. Scott-Moncrieff JC, Treadwell NG, McCullough SM, et al. Hemostatic abnormalities in dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc 2001; 37(3):220-227.
21. McManus PM, Craig LE. Correlation between leukocytosis and necropsy findings in dogs with immune-mediated hemolytic anemia: 34 cases (1994-1999). J Am Vet Med Assoc 2001; 218(8):1308-1313.
22. Sinnott VB, Otto CM. Use of thromboelastography in dogs with immune-mediated hemolytic anemia: 39 cases (2000-2008). J Vet Emerg Crit Care 2009; 19(5):484-488.
23. Mohren M, Markmann I, Dworschak U, et al. Thromboembolic complications after splenectomy for hematologic diseases. Am J Hematol 2004; 76(2):143-147.
24. Emerson GG, Herndon CN, Sreih AG. Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy 2002; 22(12):1638-1641.
25. Lee YJ, Shin JU, Lee J, et al. A case of deep vein thrombosis and pulmonary thromboembolism after intravenous immunoglobulin therapy. J Korean Med Sci 2007; 22(4):758-761.
26. Hendrick AM. Auto-immune haemolytic anaemia-a high-risk disorder for thromboembolism? Hematology 2003; 8(1):53-56.
27. Lobo BL, Vaidean G, Broyles J, et al. Risk of venous thromboembolism in hospitalized patients with peripherally inserted central catheters. J Hosp Med 2009; 4(7):417-422.
28. Zheng YN, Yu HJ, Hou JX, et al. Lactadherin and procoagulant activities of red blood cells in cyclosporine induced thrombosis. Chin Med J (Engl) 2009; 122(14):1674-1680.
29. Turpie AG, Esmon C. Venous and arterial thrombosis-pathogenesis and the rationale for anticoagulation. Thromb Haemost 2011; 105(4):586-596.
30. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451(7181):914-918.
31. Weiss DJ, Brazzell JL. Detection of activated platelets in dogs with primary immune-mediated hemolytic anemia. J Vet Intern Med 2006; 20(3):682-686.
32. Pesillo SA, Freeman LM, Rush JE. Assessment of lipid peroxidation and serum vitamin E concentration in dogs with immune-mediated hemolytic anemia. Am J Vet Res 2004; 65(12):1621-1624.
33. Piek CJ, Brinkhof B, Teske E, et al. High intravascular tissue factor expression in dogs with idiopathic immune-mediated haemolytic anaemia. Vet Immunol Immunopathol 2011.
34. Wells R, Guth A, Lappin M, et al. Anti-endothelial cell antibodies in dogs with immune-mediated hemolytic anemia and other diseases associated with high risk of thromboembolism. J Vet Intern Med 2009; 23(2):295-300.
35. Helmond SE, Polzin DJ, Armstrong PJ, et al. Treatment of immune-mediated hemolytic anemia with individually adjusted heparin dosing in dogs. J Vet Intern Med 2010; 24(3):597-605.
36. Breuhl EL, Moore G, Brooks MB, et al. A prospective study of unfractionated heparin therapy in dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc 2009; 45(3):125-133.
37. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359(9):938-949.
38. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost 2001; 85(6):958-965.
39. Smith SA. The cell-based model of coagulation. J Vet Emerg Crit Care 2009; 19(1):3-10.
40. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 2009; 108(5):1447-1452.
41. Owens AP 3rd, Mackman N. Tissue factor and thrombosis: the clot starts here. Thromb Haemost 2010; 104(3):432-439.
42. Mackman N. On the trail of microparticles. Circ Res 2009; 104(8):925-927.
43. Burnier L, Fontana P, Kwak BR, et al. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009; 101(3):439-451.
44. Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011; 108(10):1284-1297.
45. Brooks MB, Randolph J, Warner K, et al. Evaluation of platelet function screening tests to detect platelet procoagulant deficiency in dogs with Scott syndrome. Vet Clin Pathol 2009; 38(3):306-315.
46. Brooks MB, Catalfamo JL, Brown HA, et al. A hereditary bleeding disorder of dogs caused by a lack of platelet procoagulant activity. Blood 2002; 99(7):2434-2441.
47. Zwaal RF, Comfurius P, Bevers EM. Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 2005; 62(9):971-988.
48. Harmening DM. Introduction to hemostasis, In: Harmening DM. ed. Clinical Hematology and Fundamentals of Hemostasis. Philidelphia: F.A. Davis Company; 2009; pp. 543-577.
49. Brooks MDL. Feline factor XII deficiency. Compend Contin Educ Pract Vet 2006; 28(2):148-156.
50. Mackman N, Becker RC. DVT: a new era in anticoagulant therapy. Arterioscler Thromb Vasc Biol 2010; 30(3):369-371.
51. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202(2):271-281.
52. Leger AJ, Jacques SL, Badar J, et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 2006; 113(9):1244-1254.
53. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88(2):186-193.
54. Krone KA, Allen KL, McCrae KR. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep 2010; 12(1):53-57.
55. Tufano A, Guida A, Di Minno MN, et al. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost 2011; 37(3):267-274.
56. Palmer KG, King LG, Van Winkle TJ. Clinical manifestations and associated disease syndromes in dogs with cranial vena cava thrombosis: 17 cases (1989-1996). J Am Vet Med Assoc 1998; 213(2):220-224.
57. Laurenson MP, Hopper K, Herrera MA, et al. Concurrent diseases and conditions in dogs with splenic vein thrombosis. J Vet Intern Med 2010; 24(6):1298-1304.
58. Thompson MF, Scott-Moncrieff JC, Brooks MB. Effect of a single plasma transfusion on thromboembolism in 13 dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc 2004; 40(6):446-454.
59. Kidd L, Stepien RL, Amrheiw DP. Clinical findings and coronary artery disease in dogs and cats with acute and subacute myocardial necrosis: 28 cases. J Am Anim Hosp Assoc 2000; 36(3):199-208.
60. Whelan MF, O'Toole TE, Chan DL, et al. Use of human immunoglobulin in addition to glucocorticoids for the initial treatment of dogs with immune-mediated hemolytic anemia. J Vet Emerg Crit Care 2009; 19(2):158-164.
61. Hoffman PC. Immune hemolytic anemia-selected topics. Hematology Am Soc Hematol Educ Program 2009:80-86.
62. Thachil J. Autoimmune haemolytic anaemia-an under-recognized risk factor for venous thromboembolism. Transfus Med 2008; 18(6):377-378.
63. Ridyard AE, Shaw DJ, Milne EM. Evaluation of platelet activation in canine immune-mediated haemolytic anaemia. J Small Anim Pract 2010; 51(6):296-304.
64. Butenas S, Orfeo T, Mann KG. Tissue factor activity and function in blood coagulation. Thromb Res 2008; 122(Suppl 1):S42-S46.
65. Mackman N. Tissue-specific hemostasis: role of tissue factor. J Thromb Haemost 2008; 6(2):303-305.
66. Frei AC, Guo Y, Jones DW, et al. Vascular dysfunction in a murine model of severe hemolysis. Blood 2008; 112(2):398-405.
67. Setty BN, Betal SG, Zhang J, et al. Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia. J Thromb Haemost 2008; 6(12):2202-2209.
68. Solovey A, Kollander R, Milbauer LC, et al. Endothelial nitric oxide synthase and nitric oxide regulate endothelial tissue factor expression in vivo in the sickle transgenic mouse. Am J Hematol 2010; 85(1):41-45.
69. Belcher JD, Marker PH, Weber JP, et al. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 2000; 96(7):2451-2459.
70. Kjelgaard-Hansen M, Goggs R, Wiinberg B, et al. Use of serum concentrations of interleukin-18 and monocyte chemoattractant protein-1 as prognostic indicators in primary immune-mediated hemolytic anemia in dogs. J Vet Intern Med 2011; 25(1):76-82.
71. Ataga KI. Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica 2009; 94(11):1481-1484.
72. Chung SM, Bae ON, Lim KM, et al. Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol 2007; 27(2):414-421.
73. Setty BN, Betal SG. Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine-positive erythrocytes. Blood 2008; 111(2):905-914.
74. Gayen Betal S, Setty BN. Phosphatidylserine-positive erythrocytes bind to immobilized and soluble thrombospondin-1 via its heparin-binding domain. Transl Res 2008; 152(4):165-177.
75. Wandersee NJ, Tait JF, Barker JE. Erythroid phosphatidyl serine exposure is not predictive of thrombotic risk in mice with hemolytic anemia. Blood Cells Mol Dis 2000; 26(1):75-83.
76. Thachil J. Immature reticulocytes and its relevance to thrombosis. Ann Hematol 2008; 87(12):1025-1026.
77. Thachil J. The possible role of reticulocytes in sickle cell disease associated thromboembolism. Hematology 2008; 13(1):68-70.
78. Setty BN, Kulkarni S, Stuart MJ. Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. Blood 2002; 99(5):1564-1571.
79. Wandersee NJ, Olson SC, Holzhauer SL, et al. Increased erythrocyte adhesion in mice and humans with hereditary spherocytosis and hereditary elliptocytosis. Blood 2004; 103(2):710-716.
80. Davizon P, Lopez JA. Microparticles and thrombotic disease. Curr Opin Hematol 2009; 16(5):334-341.
81. Freyssinet JM, Toti F. Formation of procoagulant microparticles and properties. Thromb Res 2010; 125(Suppl 1):S46-S48.
82. Manly DA, Wang J, Glover SL, et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res 2010; 125(6):511-512.
83. Rodrigues CA, Ferrarotto R, Kalil Filho R, et al. Venous thromboembolism and cancer: a systematic review. J Thromb Thrombolysis 2010; 30(1):67-78.
84. Tsuchiya R, Akutsu Y, Ikegami A, et al. Prothrombotic and inflammatory effects of intravenous administration of human immunoglobulin G in dogs. J Vet Intern Med 2009; 23(6):1164-1169.
85. Horgan JE, Roberts BK, Schermerhorn T. Splenectomy as an adjunctive treatment for dogs with immune-mediated hemolytic anemia: ten cases (2003-2006). J Vet Emerg Crit Care 2009; 19(3):254-261.
86. Van Zaane B. Systematic review on the effect of glucocorticoid use on procoagulant, anticoagulant andfibrinolytic factors. J Thromb Haemost 2010.
87. Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 2005; 31(6):681-690.
88. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119(1 Suppl):64S-94S.
89. Wiedermann CJ. Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis. Crit Care 2006; 10(1):209.
90. Hoppe B, Burmester GR, Dorner T. Heparin or aspirin or both in the treatment of recurrent abortions in women with antiphospholipid antibody (syndrome). Curr Opin Rheumatol 2011; 23(3):299-304.
91. Stief TW. Thrombin generation by hemolysis. Blood Coagul Fibrinolysis 2007; 18(1):61-66.
92. Fries D. Thrombosis prophylaxis in critically ill patients. Wien Med Wochenschr 2011; 161(3-4):68-72.
93. Mischke RH, Schuttert C, Grebe SI. Anticoagulant effects of repeated subcutaneous injections of high doses of unfractionated heparin in healthy dogs. Am J Vet Res 2001; 62(12):1887-1891.
94. Bethel M. Coagulation Methods, In: Harmening DM. ed. Clinical Hematology and Fundamentals of hemostasis. Philidelphia: FA Davis Company; 2009, pp. 849-881.
95. Spiess BD. Treating heparin resistance with antithrombin or fresh frozen plasma. Ann Thorac Surg 2008; 85(6):2153-2160.
96. Brooks MB. Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma. Vet Clin Pathol 2004; 33(4):208-214.
97. Diquelou A, Barbaste C, Gabaig AM, et al. Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs. Vet Clin Pathol 2005; 34(3):237-242.
98. Mischke R, Jacobs C. The monitoring of heparin administration by screening tests in experimental dogs. Res Vet Sci 2001; 70(2):101-108.
99. Mischke R. Heparin in vitro sensitivity of the activated partial thromboplastin time in canine plasma depends on reagent. J Vet Diagn Invest 2003; 15(6):588-591.
100. Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119(2):104-109.
101. Scott KC, Hansen BD, DeFrancesco TC. Coagulation effects of low molecular weight heparin compared with heparin in dogs considered to be at risk for clinically significant venous thrombosis. J Vet Emerg Crit Care (San Antonio) 2009; 19(1):74-80.
102. Lunsford KV, Mackin A, Langston VC, et al. Pharmacokinetics of subcutaneous low molecular weight heparin (enoxaparin) in dogs. J Am Anim Hosp Assoc 2010; 45(6):261-267.
103. Mischke R, Fehr M, Nolte I. Efficacy of low molecular weight heparin in a canine model of thromboplastin-induced acute disseminated intravascular coagulation. Res Vet Sci 2005; 79(1):69-76.
104. Rumbaut RE, Thiagarajan P. Platelet-Vessel Wall Interactions in Hemostasis and Thrombosis. San Rafael (CA): Morgan & Claypool Life Sciences; 2010. Available at: http://www.ncbi.nlm.nih.gov/books/NBK53450/.[Last accessed Sep 29, 2012].
105. Sharpe KS, Center SA, Randolph JF, et al. Influence of treatment with ultralow-dose aspirin on platelet aggregation as measured by whole blood impedance aggregometry and platelet P-selectin expression in clinically normal dogs. Am J Vet Res 2010; 71(11):1294-1304.
106. Rackear DG. The effect of three different dosages of acetylsalicylic acid on canine platelet aggregation. J Am Anim Hosp Assoc 1988; 24(1):23-26.
107. Heather Graham A, Leib MS. Effects of prednisone alone or prednisone with ultralow-dose aspirin on the gastroduodenal mucosa of healthy dogs. J Vet Intern Med 2009; 23(3):482-487.
108. Brainard BM, Kleine SA, Papich MG, et al. Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs. Am J Vet Res 2010; 71(7):822-830.
109. Schouten M, Wiersinga WJ, Levi M, et al. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008; 83(3):536-545.
110. LaRosa SP. Clinical trials of novel anticoagulants for severe sepsis: a tale of three molecules. Advances in Sepsis 2004; 4(1):17-23.
111. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286(15):1869-1878.
112. Paikin JS, Wright DS, Eikelboom JW. Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials. Blood Rev 2011; 25(3):123-129.
113. Tsiara S, Pappas K, Boutsis D, et al. New oral anticoagulants: should they replace heparins and warfarin? Hellenic J Cardiol 2011; 52(1):52-67.
114. Azevedo LC, Pedro MA, Laurindo FR. Circulating microparticles as therapeutic targets in cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2007; 2(1):41-51.